medRxiv preprint doi: https://doi.org/10.1101/2021.05.11.21257024; this version posted May 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Machine learning enabled subgroup analysis with real-world data to inform better clinical trial design

- 3 Jie Xu^{1,*}, Hao Zhang^{1,*}, Hansi Zhang², Jiang Bian^{2,#}, Fei Wang^{1,#}
- ⁵ ¹Department of Population Health Sciences. Weill Cornell Medical College. Cornell University.
- ²Department of Health Outcomes and Biomedical Informatics. College of Medicine. University of
 Florida.
- 7 FIOI 8
- 9 ^{*}Equal Contribution.
- 10

- 11 [#]Corresponding Authors.
- 12 13 Jiang Bian.
- 14 2197 Mowry Rd, Suite 122.
- 15 Gainesville. FL. 32610. USA.
- 16 <u>bianjiang@ufl.edu</u>
- 17
- 18 Fei Wang.
- 19 425 East 61 Street.
- 20 New York. NY 10065. USA.
- 21 <u>few2001@med.cornell.edu</u>
- 22
- 23 Number of words (main text): 4799

medRxiv preprint doi: https://doi.org/10.1101/2021.05.11.21257024; this version posted May 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

24 Abstract


25 Restrictive eligibility criteria for clinical trials may limit the generalizability of treatment 26 effectiveness and safety to real-world patients. In this paper, we propose a machine learning 27 approach to derive patient subgroups from real-world data (RWD), such that the patients within 28 the same subgroup share similar clinical characteristics and safety outcomes. The effectiveness 29 of our approach was validated on two existing clinical trials with the electronic health records 30 (EHRs) from a large clinical research network. One is the donepezil trial for Alzheimer's disease 31 (AD), and the other is the Bevacizumab trial on colon cancer (CRC). The results show that our 32 proposed algorithm can identify patient subgroups with coherent clinical manifestations and 33 similar risk levels of encountering severe adverse events (SAEs). We further exemplify that 34 potential rules for describing the patient subgroups with less SAEs can be derived to inform the 35 design of clinical trial eligibility criteria.

36 Introduction

37 Randomized controlled trials (RCTs) are the golden standard for investigating drug 38 effectiveness (1). In designing an RCT, stringent eligibility criteria (EC) need to be applied to 39 appropriately define a study population so that the drug effectiveness can be reliably and safely 40 evaluated. In practice, trial designers often adopt eligibility criteria from existing similar trials, 41 without too much consideration on their applicability and adaptability to the new trials. Moreover, 42 many pivotal Phase III clinical trials continue to apply the same highly restrictive eligibility criteria 43 as in the corresponding Phase I and Phase II trials. These oftentimes make the eligible trial participants not representative of the real-world patient population who will receive the treatment 44 45 (2). For example, the elderlies are often excluded from cancer and Alzheimer's disease drug 46 development trials and are therefore under-represented among the primary target populations 47 for these drugs (3, 4).

Although excessive or overly restrictive EC may lower the risk of the study populations for encountering adverse events (5-7), they usually lead to low population representativeness (thus, low trial generalizability), and subsequently, treatment effectiveness could be reduced, and the likelihood of adverse outcomes could increase when the treatment entered real-world clinical practice (8). Therefore, as recommended by regulatory agencies such as the U.S. Food and Drug Administration (FDA), broadening eligibility criteria during enrollment to increase the diversity of the clinical trial population and thus improve generalizability is an important trend (9).

55 Trial generalizability is largely dependent on the representativeness of the study population with 56 respect to target population to which the study results are intended to be applied (8). In recent 57 years, the rapid adoption of electronic health records (EHR) systems has led to large integrated 58 clinical data warehouses and interoperable data networks, which made it possible for accumulating large amounts of real-world patient data. Such data provide us a unique 59 60 opportunity for simulating the study and target populations of clinical trials. The goal of this study 61 is to develop machine learning approaches for mining insights from RWD that could be 62 informative of clinical trial eligibility criteria design. In particular, to account for the heterogeneity 63 of the real-world population, we introduce a novel transparent and outcome-guided probabilistic 64 model to identify the subphenotypes who took a specific medication (Fig. 1). The patients within the same subphenotype do not just share similar clinical characteristics, but also face a similar 65 risk of encountering severe adverse events (SAEs) after they take the drug. We assume certain 66 67 compositions (co-occurrence patterns) of the clinical events within an individual's EHR can 68 determine those subphenotypes and propose a novel weakly supervised clinical topic modeling 69 approach to identify those subphenotypes. Here each clinical topic represents a certain clinical 70 event composition pattern learned from the patient EHRs.



71

Fig. 1 Model overview. Clinical events including demographics, diagnoses, and medications were extracted from RWD to represent patients. Supervised Poisson factor analysis (PFA) is applied to identify patient subgroups with coherent clinical latent topics and outcomes measured by SAEs. Subgroups with less SAEs can be derived to inform the design of clinical trial eligibility criteria.

77 We evaluated our algorithm with two real-world clinical trials: (1) a hallmark randomized Phase 78 III trial (i.e., NCT00478205) that compares the effects of 23 mg to 10 mg Donepezil in treating 79 patients with Alzheimer's disease that led to the FDA approval of the 23 mg Donepezil; and (2) 80 another randomized Phase III trial studying two different combination chemotherapy regimens 81 with or without bevacizumab (trade name Avastin) in high-risk stage II/III colon cancer patients. 82 We used RWD data from the OneFlorida Clinical Research Consortium -- a statewide clinical 83 data warehouse containing large collections of linked EHR, administrative claims, vital statistics, 84 and cancer registry data among others, covering more than 15 million (~60%) Floridians (10). 85 Our results showed that, for both trials, 1) a significant number of real-world patients who satisfied the ECs and took the drug suffered from SAEs; 2) our model can clearly identify the 86 87 patient subgroups who are more likely to suffer or not suffer from SAEs as subphenotypes in a transparent and interpretable way. We have also inferred the clinical topics from the 88

subphenotypes with or without SAEs, which reveal meaningful combinations of clinical features

90 across multiple data types and provide data-driven recommendations for refining the ECs of

91 clinical trials.

92 **Results**


93

94 Target population of the donepezil clinical trial. NCT00478205 is a double-blind, double-95 dummy trial that compares different dosages (23 mg vs. 10 mg) of donepezil for treating 96 patients with moderate to severe Alzheimer's disease (11). The real-world individual-level EHR 97 data are from the OneFlorida Clinical Research Consortium. We constrained the target 98 population as those who (1) were diagnosed with AD, and (2) treated with donepezil. A total of 99 4,998 unique patients (mean (SD) age, 77.53 (9.9) years) were identified from OneFlorida (Fig. 100 2b, Table 1).

101 To determine whether a patient experienced SAEs related to donepezil, we first compiled the list 102 of SAEs reported in the original trial in ClinicalTrials.gov, and then identified relevant diagnosis 103 codes (i.e., International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification 104 [ICD-9/10-CM]) for each SAE. Based on the severity grading scale defined in the Common 105 Terminology Criteria for Adverse Events (CTCAE) (12), adverse events leading to 106 hospitalization or mortality are grade 3 and above are considered as SAEs in our study. Further, we defined that the SAE diagnosis codes have to occur 1) after the first donepezil treatment, 107 108 and 2) before 30 days after the last donepezil treatment (Fig. 2a). Among the patients in our 109 target population, 3,063 (61.3%) had no SAE while 1,935 (38.7%) had at least one SAE. We 110 dropped the ECs which are not computable (e.g., subjective eligibility criteria such as "written 111 informed consent" is not computable, but also not going to affect our analysis, since we can safely assume all patients treated with donepezil in the real-world are consented) and extracted 112 113 study traits corresponding to each computable EC from the OneFlorida data (Table 1).

114 We first represent each patient using the extracted traits as a vector and check whether patients 115 with and without SAEs can be well separated. Fig. 2c shows the 2D embeddings of patient traits 116 with Uniform Manifold Approximation and Projection (UMAP) (13). We color each sample 117 based on whether the patient had SAEs or not. As shown in the figure, the two clusters, patients 118 with (#SAE>0) vs. without (#SAE=0) are mixed up with each other, which indicates that the trial 119 ECs cannot guarantee the safety for real-world patients. In addition, we examined the 120 differences of the study traits value distributions between the two groups through Chi-square 121 tests and summarized the results in Table 1, from which we observe that many traits were not 122 significantly different (statistical sense, with p>0.05) including memantine (p=0.145), 123 antidepressant (p=0.590), basal/squamous cell carcinoma of the skin (p=0.275), galantamine 124 (p=0.190), severe lactose intolerance (p=0.219), and clinically significant Hepatic (p=0.105). 125 This suggests that the trial ECs can further be optimized with real-world evidence. 126

a Definition of key dates



127

Fig. 2 The donepezil trial for Alzheimer's disease. a Definition of key dates; b Selection of
 target population; c Traits distribution with UMAP among two patients' groups with or without
 SAE.


Study design of the donepezil clinical trial. The beginning of the treatment is termed the index date. We set the index date in our donepezil trial to the first (ever) observed prescription date of donepezil. We refer to the observed time before the index date as the baseline period and use the information (i.e., demographic, diagnosis and medication history) collected during that time period for analysis. The period from the index date to the last donepezil prescription plus 30 days was set as the follow-up period, from which the SAE information is collected. Fig. 2a illustrates the key dates in our study design.

We applied supervised Poisson factor analysis (SPFA) to the collected information and used the occurrence of SAE as the supervision to guide the learning process of PFA. Similar to other topic modeling approaches (14), SPFA first compressed the clinical events into a set of overlapping groups (i.e., topics). Novel patient representations are derived on top of these topics (which are groups of clinical events that tend to co-appear in the same visit within the RWD). K-means clustering is then performed on these new patient representations to identify the clusters as subphenotypes. To choose the optimal number of topics K, we used all samples to learn the supervised topic model and then evaluated the topic coherence by normalized pointwise mutual information (NPMI) value (15), and the classification performance by ROC-AUC. We set K=40 for subsequent analyses as it achieved the highest ROC-AUC with large topic coherence values (Supplementary Fig. 1). The model robustness with respect to K will be discussed in the methods.

150 As discussed in (16), according to the silhouette score (17), we select the most appropriate 151 number of clusters that provides the largest silhouette score. As a result, six clusters were 152 derived with K-means for patients who had been diagnosed with AD and treated with Donepezil 153 (Fig. 3a). Among the six clusters, two patient subgroups emerged: (1) the SAE group (#SAE>0) 154 containing clusters 4, 5, and 6, and (2) the non-SAE group (#SAE=0) including clusters 1, 2 and 155 3. As shown in Fig. 4a, the two patient subgroups (i.e., #SAE=0 vs. #SAE>0) are well separated. 156 Specifically, for the SAE group, 1,915 out of total 1,935 patients (99.0%) encountered SAE 157 events; for non-SAE group, 3,014 out of 3,063 patients (98.4%) did not have any SAE events.


158

159 We examined the distribution of the 40 topics across the two subgroups (Fig 4b). According to i) 160 the mean topic weights (MTW) over all samples (evaluation for the usage of each topic on the 161 cohort) and ii) Mann–Whitney U (MWU) test (18) on MTW of SAE subgroup (#SAE>0) versus 162 non-SAE subgroup (#SAE=0) (evaluation for difference of topic usage between two groups), 18 163 typical topics were selected to be analyzed detailly. Specifically, 15 topics (except for T4, T9, 164 and T13 in Fig 2c) whose MWU p-value of SAE subgroup versus non-SAE subgroup are 165 smaller than 0.05 (significant difference between two groups) while MTW on all samples are 166 larger than 0.1 were selected. Of the 15 typical significant-difference topics, 10 topics (T1~T3, 167 T5~T8, T16~T18, denoted by red in Fig. 3c) were characterized as likely to align with the SAE 168 subgroup (#SAE>0) and the other 5 topics (T10~T12, T14~T15, denoted by blue in Fig. 3c) 169 align with the other non-SAE subgroup (#SAE=0). Besides, 3 topics (T4, T9, and T13) whose p-170 values are larger than 0.05 but MTW on all samples are the top-three largest ones were also 171 selected. These 3 topics (T4, T9, and T13) are shared by all clusters.




b Topic distributions of each cluster

a Data visualization with UMAP




c Top clinical features from certain disease topics



173

Fig. 3 Clustering results of AD target population. a Data visualization with UMAP; b Topic distributions of each cluster; c Top clinical features from certain disease topics, where the red, blue, and green topics represent the commonly used topics for clusters 4, 5, 6 (most of samples are with SAE>0), clusters 1, 2, 3 (most of samples are with SAE=0), and all clusters, respectively.



180

Fig. 4 Donepezil clinical trial. a Visualization of clustering results; b Mean topic weight (MTW)
 of all topics on two groups, where x-axis is the topic index and y-axis is the MTW of each topic
 on two subgroups.

184

185 We then examined the relevance of our learned disease topics by qualitatively assessing the 186 coherence of the five most prevalent clinical events (i.e., diagnosis and medication codes) for 187 each topic (19). We interpreted these 18 topics based on these clinical events and found that 188 many of them were specific to different diseases (Fig 3c). These 18 topics can be divided into 189 three categories. Specifically, i) T4, T9, and T13 includes dementia, memory loss and cognitive 190 impairment related events, which are commonly used among all clusters. These topics 191 represent the common diseases and drugs in the cohort. ii) T1 is related to cardiovascular 192 diseases, T2 is related to gastrointestinal diseases, T3 is about respiratory disorders. T5 is 193 related to psychotic disorders, especially Schizophrenia and relevant treatments (anticholinergic 194 agents) (20). T6 is related to endocrine disorders. T7 is about metabolism disorders such as 195 mineral metabolism disorder. T8 includes lipoid metabolism and secondary malignant neoplasm 196 or cancer of the liver. There have been prior studies showing the relationship between these two 197 types of diseases (21). T16 includes various conditions or disorders of brains, which is closely 198 related to AD. T17 talks about the diseases and treatments of esophagus such as 199 gastroesophageal reflux disease (GERD). T18 is about obesity and some related complications 200 and drugs. Six clusters were derived which is characterized by some related clinical topics: 201 cluster 1 (N=1811; 36.23%), patients with disorders of ears or eyes (T11 and T14); cluster 2 202 (N=939; 18.79%), patients with diseases of urinary system (T12 and T15); cluster 3 (N=331; 203 6.62%), patients with depression or mood disorder (T10 and T13); cluster 4 (N=667; 13.35%), 204 patients with disorders of endocrine and metabolism (T6, T7, and T8); cluster 5 (N=548; 205 10.96%), patients with different diseases of brain (T1, T5, and T16); cluster 6 (N=702; 14.05%), 206 patients with diseases of digestive and respiratory systems (T2, T3, and T17).

The topics, commonly used in the SAE subgroup, may have close relation with exclusion criteria in EC. T11 and T14 are related to diseases of ears such as hearing loss in T11 and otitis media in T14 with related drugs, which have some shared characteristics with AD (22). T12 and T15 related to various diseases are about male genital organs such as hyperplasia of prostate and urinary tract disorder. T10 is associated with mood disorders and depression, where their relationship to dementia and AD is unclear (23). These topics are mostly related to relatively mild conditions with no direct connection to the diagnosis of AD. In other words, most phenotypes associated with the non-SAE subgroup are mild aging-related chronic comorbidities that are common in older adults and do not lead to serious adverse effects. Therefore, diseases which are more associated with the non-SAE patient subgroup may have a lower probability of causing adverse serious events.

We further analyzed the association between the inferred topics with the SAE subgroup and the extracted computable eligibility criteria. We will explain why our model is more powerful in distinguishing two subgroups compared to traits.

Align with exclusion criterion in clinical trials. Firstly, we found that topics (T1~T8) aligned with the SAE patient subgroup (#SAE>0) are highly associated with the exclusion criteria of the donepezil trial. Here, [Ex] represents the "exclusion criterion" of clinical trials.

- "[Ex] Patients with evidence of clinically significant, active gastrointestinal, renal, hepatic,
 respiratory, endocrine, or cardiovascular system disease (including history of lifethreatening arrhythmias)."
- We found T1 (cardiovascular), T2 (gastrointestinal), T3 (respiratory), T6 (endocrine) are highly related to this exclusion criterion. Disorders of lipoid metabolism (i.e., T8) is a major contributing factor that mediates the development of cardiovascular diseases, especially atherosclerosis (24).
- "[Ex] Patients with dementia complicated by other organic diseases or Alzheimer's disease with delirium."

We found T4 (delirium) is related to this criterion. Although T4 is a topic shared by non-SAE subgroup (cluster 1) and SAE subgroup (clusters 4, 5, 6), its proportion and MTW are higher in SAE group (Fig 3b and 4b).

- "[Ex] Patients with psychiatric disorders affecting the ability to assess cognition such as schizophrenia, bipolar or unipolar depression. Patients with clinically significant sleep disorders will also be excluded unless these are controlled by treatment and clinically stable for > 3 months prior to screening."
- 240 We found T5 (psychotic disorders) is related to this criterion.
- "[Ex] Patients with any conditions affecting absorption, distribution, or metabolism of the study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance)."
- We found T7 is related to this criterion. T7 is characterized as other disorders of metabolism include disorders of fluid, electrolyte, and acid-base balance. Acid-base and electrolyte homeostasis is essential for the proper functioning of many metabolic processes and organ functions in the body (25). Phenotypes in T7 seem to have effects on absorption or metabolism of the study medication.
- "[Ex] Patients with a history of cancer (does not include basal or squamous cell carcinoma of the skin) treated within 5 years prior to study entry, or current evidence of


- malignant neoplasm, recurrent, metastatic disease. Males with localized prostate cancer
 requiring no treatment would not be excluded."
- Although we annotated T8 to the disorder of lipoid metabolism, it also includes secondary malignant neoplasm or cancer of the liver. As the disorder of lipid metabolism plays an important role in carcinogenesis and development, we concluded T8 is also related to this criterion.

257 Different from and move beyond exclusion criteria in clinical trials. Secondly, we found 258 that some topics (T16~T18) have no direct connections with exclusion criteria. These topics 259 describe some diseases, such as disorders of the brain in T16, diseases of esophagus in T17, 260 and obesity in T18, which may have a severe impact for older people. For example, in (26), 261 authors discussed associations of obesity with numerous life-threatening diseases. In (27), 262 authors discussed the potential life-threatening gastroesophageal reflux disease (GERD). In 263 other words, our method may discover some diseases that have potential outcomes of serious 264 adverse events for elder patients, but are ignored by the original EC. This is the first reason why 265 our method, learning knowledge from more abundant features, can separate SAE and non-SAE 266 subgroups well compared with original traits from EC. Furthermore, even for one disease that 267 appears in both SAE-associated topics and EC, more abundant features provide more detailed 268 insights. For example, for gastrointestinal disease, EC only said "[Ex] Patients with evidence of 269 clinically significant active gastrointestinal disease", which may be a coarse description. 270 However, the learned topics, T2 and T17, discover more detailed diseases or drugs about 271 gastrointestinal disease.

There are also eligibility criteria that have no apparent relations with these inferred topics likely due to two main reasons: (1) since we did not use procedure codes and laboratory tests in the topic modeling process, eligibility criteria related to procedures and lab tests were missing in these inferred topics; and (2) there are eligibility criteria that are not used to ensure patient safety but to ensure treatment efficacy.

- 277 Target population of the bevacizumab (Avastin) clinical trial. To demonstrate the 278 generalizability of our approach, we analyzed another RCT (NCT00112918) which studied a 279 combination chemotherapy with or without bevacizumab in treating patients who have 280 undergone surgery for high-risk stage II or stage III colon cancer. Specifically, the trial studied 281 three combination chemotherapies: (1) the control arm, a standard-of-care (SoC) treatment, 282 FOLFOX4 (i.e., intermittent fluorouracil/leucovorin with oxaliplatin), (2) FOLFOX4 plus 283 bevacizumab, and (3) XELOX (i.e., capecitabine with oxaliplatin) plus bevacizumab. In our 284 RWD analysis, we set the target population as patients who (1) were diagnosed with colorectal 285 cancer (CRC), and (2) treated with FOLFOX4 (Fig. 5(b), Table 2). Since FOLFOX4 was the SoC 286 treatment, patients who were treated with FOLFOX4 in the real-world could potentially benefit 287 from the new combination chemotherapies investigated in this trial. A total of 739 patients 288 (mean age, 57.49 with a standard deviation of 11.2 years old) were identified (out of a total of 289 47,492 CRC patients) from OneFlorida.
- 290 Similar to the Donepezil trial, we defined the index date as the date of first FOLFOX4 treatment 291 after CRC diagnosis. The baseline period was defined as the time period before the index date,

292 and the follow-up period was defined as the time period between index date and the last 293 FOLFOX4 treatment date plus 30 days. SAE events were collected from the follow-up period. 294 This study design is depicted in Fig. 4(a). Among all CRC patients who received FOLFOX4 after 295 diagnosis, 347 (47.0%) had no SAE, while 392 (53.0%) had at least one SAE. We examined the 296 computability of each eligibility criterion and constructed queries to extract study traits 297 corresponding to the computable ones based on the OneFlorida data. The identified traits 298 included patient demographics (e.g., age) and medical history (e.g., medication, treatment). We 299 conducted Chi-square tests on the two patient subgroups, i.e., patients had SAEs (#SAE>0) vs 300 patients who did not (#SAE>0). We found that the p values of most study traits are larger than 301 0.05, except for metastatic disease (p=0.026), parenteral anticoagulants (p<0.001), myocardial 302 infarction (p<0.001) and significant and thrombolytic agent (p=0.003). The p value of the trait 303 related to "inability to take oral medication" was smaller than 0.05 after adjusting for 304 demographics (Table 2).




305 306

Fig. 5 The Bevacizumab (Avastin) clinical trial for colon cancer. a Definition of key dates; b
 Selection of the target population; c Traits distribution with UMAP among the two patients'
 groups with or without SAEs.

311 Similar to the donepezil trial, we applied SPFA to the CRC target population. The patient 312 features we collected from the baseline period include demographics, diagnosis (as phecodes) 313 and medications (as ATC classes)). Similar to what we have done in analysis of Donepezil trail, 314 we evaluated the topic coherence by NPMI value (15), and the classification performance by 315 ROC-AUC to decide the number of topics. We set the number of topics K=40 since it achieves 316 higher ROC-AUC and NPMI (Supplementary Fig. 1). Fig. 6a shows the UMAP embeddings of 317 new patient representations induced by SPFA. From the figure we can observe two well-318 separated patient subgroups, which can be identified by K-means clustering. One group (red) is 319 mostly associated with SAE (317 of 347 patients, or 91.4% of the patients in this subgroup 320 encountered SAE) and the other group (blue) is free of SAE (393 patients). We checked the 321 patient group proportions for 40 topics in the two clusters (Fig. 6b). Of the 40 topics in the model, 322 patients' proportion in 9 topics were larger than 0.075 and visually very different in two patient 323 subgroups. Of these 9 typical topics, 6 topics (T1~T6) were characterized as likely to align with 324 the SAE subgroup (#SAE>0) and the other 3 topics (T7~T9) align with the non-SAE subgroup 325 (#SAE=0). We annotated the 9 topics based on the top EHR codes and found that most of the 326 inferred topics were specific to different diseases or treatments (Fig.7, Supplementary Fig. 3).

327 Among all 40 topics, similar to the topic selection method for donepezil trial, we selected 13 328 topics for detailed analysis (Fig. 7). According to the MTW on two groups (Fig. 6b, 329 Supplementary Table 2), these topics can be divided into three categories: i) T1~T6 and 330 T12~T13, represented as red, are associated with SAE subgroup; ii) T7~T9, represented as 331 blue, aligned with the non-SAE subgroup, contain relatively mild diseases and were not directly 332 related to the diagnosis of colon cancer; iii) T10~T11, represented as green, are often shared 333 on two subgroups. Specifically, T1 is annotated to the use of corticosteroids, with the three of 334 the top five codes being specific corticosteroids treatments. T2 is related to antithrombotic 335 agents. T3 is about malignant neoplasm, where the first three main codes are all correlated with 336 secondary malignant neoplasm and one code is about cancer, and one code is hormones and 337 related preparations drug class which is used to treat cancer. T4 is related to clinically 338 significant (i.e., active) cardiovascular disease. T5 is also related to cancer, but more specific to 339 the liver. Phenotypes in T6 include various kinds of disorders related to intestine, e.g., drugs for 340 peptic ulcer and gastro-oesophageal reflux disease (GORD), hemorrhage of gastrointestinal 341 tract, gastritis and duodenitis and gastric ulcer. T7 includes some commonly used drugs. T8 342 talks about the disease and treatments about urinary tract infection, which is extremely common 343 in the elderly (28). T9 is associated with gastrointestinal diseases such as nausea and vomiting. 344 T10 and T11 are some common diseases such as or hyperlipidemia or hypertension. T12 345 includes different diseases or treatments about the intestine. For example, authors in (29) 346 discussed the relations between CRC and chronic intestinal inflammation. T13 is about the 347 cancer or malignant neoplasms of digestive organs. Next, we analyze the connections of SAE-348 group related topics (the red one) with the EC in trial.

- 349 350
- 350
- 351







354 355

356

Fig. 6 Bevacizumab (Avastin) clinical trial. a Visualization of clustering results; **b** Mean topic weight for 40 topics where x-axis is the topic and y-axis is the proportion of each group in that topic.





359 Association analysis between topics and the eligibility criteria of bevacizumab (Avastin)

- trial. Firstly, we analyzed the association between the inferred topics and extracted eligibility criteria. We compared each typical topic with the criteria. We found that topics, T1~T6, aligned with the SAE subgroup (#SAE>0) are highly associated with some of the exclusion criteria in the original trial.
- "[Ex] Chronic treatment with corticosteroids (dose of ≥ 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids)."
- 366 We found T1 (*corticosteroids*) is highly related to this exclusion criterion.

- "[Ex] Current or recent (within 10 days prior to study treatment start) use of full-dose oral
 or parenteral anticoagulants or thrombolytic agents for therapeutic purposes."
 We found T2 (antithrombotic) is related to this criterion.
- "[Ex] Macroscopic or microscopic evidence of remaining tumour. Patients should never
 have had any evidence of metastatic disease (including presence of tumour cells in the
 ascites). The isolated finding of cytokeratin positive cells in bone marrow is not
 considered evidence of metastatic disease for purposes of this study.
- 374 [Ex] Other malignancies within the last 5 years (other than curatively treated basal cell 375 carcinoma of the skin and/or in situ carcinoma of the cervix).
- [Ex] Previous anti-angiogenic treatment for any malignancy; cytotoxic chemotherapy,
 radiotherapy or immunotherapy for colon cancer."
- We found T3 (malignant neoplasm) and T5 (disorders of liver) are related to these exclusion criteria. Although we annotated T5 as the disorder of liver, it also included malignant neoplasm of liver or antineoplastic agents.
- "[Ex] Clinically significant (i.e., active) cardiovascular disease. This includes, but is not limited to, the following examples: cerebrovascular accidents (\leq 6 months prior to randomization), myocardial infarction (\leq 1 year prior to randomization) ..."
- 384 We found T4 (cardiovascular) is characterized by myocardial infarction, coronary 385 atherosclerosis, angina pectoris, which is very related to this criterion.
- "[Ex] Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication."
- 388 We found T6 is related to this criterion.

389 Secondly, we analyzed the difference of learned topics with EC and discussed why our methods 390 can separate SAE and non-SAE well. Some topics, T12 and T13, are beyond the exclusion 391 criteria in trial, which provide more discriminant features to separate two subgroups. For 392 instance, T12 is about intestinal diseases, which may bring a high mortality rate and often 393 related to multiple comorbidities (30). Even for the topics that have relation with exclusion 394 criteria as discussed above, the learned clinical topics provide more detailed information. For 395 example, EC provides a rough description about corticosteroids as "Current or recent (within 10 396 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or 397 thrombolytic agents for therapeutic purposes". Compared with it, the topic T2 contains more 398 detailed drugs about corticosteroids. Therefore, these two benefits make our method provide a 399 better separation for two subgroups.

400 Similar to the findings in the donepezil trial analysis, there are some criteria which have no 401 relations with the learned topics. Some of these criteria have potential to be adjusted. For 402 example, for the exclusion criterion "History or evidence upon physical examination of central 403 nervous disease (CNS) disease (e.g., primary brain tumour, seizure not controlled with standard 404 medical therapy, any brain metastases)," Exclusion of patients with brain metastases (BMs) in 405 clinical trials is common. Although life expectancy may be reduced for some patients with BMs. and there are concerns about a potentially greater risk of neurotoxicity, our results did not 406 407 indicate CRC patients experience a higher rate of SAEs due to having history or evidence upon

physical examination of central nervous disease (CNS) disease. If these patients are excluded,
 justification for such exclusion should be provided alongside the exclusion criteria (31).

410 **Discussion**

411

412 Rigorous eligibility criteria for RCTs may make the trial participants not representative of real-413 world patients. When the trial drugs are on market and prescribed for patients, severe adverse 414 events could happen. In this paper, we developed a machine learning approach to identify the 415 patient subgroups from RWD which are more or less likely to encounter SAEs after the 416 treatment. We consider patient demographics and all clinical events, including diagnosis and 417 medications, in the baseline period for deriving the subgroups. To account for the high-418 dimensionality and SAE information, we proposed a novel supervised topic modeling approach 419 (SPFA) to achieve this goal. Our approach identified a set of clinical topics and derived novel 420 patient representations based on them, such that the patient subgroups with or without SAEs 421 can be well separated with these representations.

We validated our method on two RCTs from different disease domains: (1) NCT00478205 for AD; and (2) NCT00112918 for colorectal cancer. Tested on both trials, patient subgroup (#SAE=0) and patient subgroup (#SAE>0) can be separated well by k-means clustering using the inferred topics. The inferred topics characterized as likely to align with the patient subgroup (#SAE>0) revealed meaningful combinations of clinical features and can provide data-driven recommendations for refining the exclusion criteria of clinical trials.

428 In a recent study from Liu et al. (32) which aims at evaluating ECs for oncology trials using 429 RWD and AI, the authors quantified the representability of each study trait with SHAP (33), and 430 they tried to relax the range of each EC for broadening the participation. Only traits with 431 continuous values are considered in a one-by-one manner. Our proposed approach in this 432 paper mainly considered binary traits (continuous traits can also be incorporated with 433 appropriate discretizations followed by one-hot representations) and modeled the high-order 434 interactions of these traits as clinical topics. In addition, we also considered adding extra traits to 435 improve the representability and safety of the trial in real-world data.

436 Our study has several limitations. First, our study only leveraged the RWD from OneFlorida, 437 which is a regional clinical research network. Future investigation on larger and more diverse 438 RWD is needed to enhance the generalizability of the identified subgroups. Second, we only 439 explored structured information in RWD in this study. Lots of important information, such as 440 symptoms, clinical assessments (e.g., from radiology and pathology reports) and socioeconomic 441 status, are encoded in clinical notes. Extracting and incorporating unstructured information in 442 our study is another important direction to pursue. Third, only discrete traits have been 443 considered in this study. Continuous traits, such as lab tests, are also crucial for many RCTs. 444 Their corresponding computable counterparts in RWD should be explored as well.

445

447 Methods

448

449 Clinical trials: We selected two phase III clinical trials from ClinicalTrials.gov — a registry
 450 maintained by the National Library of Medicine (NLM) in the United States.

NCT00478205 is a double-blind, double-dummy trial aims to compare different dosages of
donepezil for treating patients with moderate to severe AD (11). We identified AD patients from
OneFlorida using ICD-9/10-CM codes (i.e., ICD-9: 331.0; ICD-10: G30.0, G30.1, G30.8, and
G30.9). Then, we used the RxNorm concept unique identifier (RXCUI) and National Drug Code
(NDC) codes to identify AD patients who took donepezil.

NCT00112918 is a randomized trial studying different combination chemotherapies (i.e. with or without bevacizumab) in treating CRC patients. Our study focused on the control arm (i.e., patients who were treated with the SoC, FOLFOX4). We identified CRC patients using ICD-9/10-CM codes (i.e., ICD-9: 153.*, 154.*, 159.0; ICD-10: C18.*, C19.*, C20.*, C26.0). Within the CRC patients, we then used the RXCUI and NDC codes of three drugs (i.e., 5-fluorouracil, leucovorin, and oxaliplatin) (Supplementary Table 3) to further identify the CRC patients who took FOLFOX4 after their CRC diagnosis.

463 Real-world patient data (RWD) from OneFlorida: We obtained individual-level patient data from 464 the OneFlorida Clinical Research Consortium (10), which contains robust longitudinal and linked 465 patient-level RWD of ~15 million (>60%) Floridians, including data from Medicaid claims, cancer 466 registries, vital statistics, and EHRs from its clinical partners. As one of the Clinical Data 467 Research Networks (CDRNs) contributing to the national Patient-Centered Clinical Research 468 Network (PCORnet), OneFlorida includes 12 healthcare organizations that provide care through 469 4.100 physicians, 914 clinical practices, and 22 hospitals, covering all 67 Florida counties. 470 OneFlorida follows the PCORnet Common Data Model (CDM) including patient demographics, 471 enrollment status, vital signs, conditions, encounters, diagnoses, procedures, prescribing (i.e., 472 provider orders for medications), dispensing (i.e., outpatient pharmacy dispensing), and lab 473 results (8).

474 We extracted the clinical events from OneFlorida data, which include demographics (i.e., age, 475 sex, race), diagnoses (i.e., ICD 9/10), and drugs (i.e., NDC/RXNorm). We calculated age based 476 on the birth date and first donepezil treatment date for AD patients, or first FOLFOX4 treatment 477 date for CRC patients. Uniform-sized bins were used to discretize the age and one-hot encoding 478 was adopted to encode age, gender and race variables. We mapped diagnosis codes to 479 Phecode which is designed to facilitate phenome-wide association studies (PheWAS) in EHRs 480 (34). Drug codes (i.e., NDC/RXNorm) were mapped to the Anatomical Therapeutic Chemical 481 (ATC) Classification System 3rd level. Finally, we concatenated all the features (demographics, 482 diagnosis and medications) to represent each patient as a binary vector.

483

Defining serious adverse events (SAEs). To define an SAE, we followed the Food and Drug Administration (FDA) Code of Federal Regulations (CFR) Title 21 definition of SAE (35). An adverse event (AE) is considered serious if, in the view of either the investigator or sponsor, it results in any of the following outcomes: 1) death; 2) a life-threatening adverse event, 3) inpatient hospitalization or prolongation of existing hospitalization, 4) disability or permanent

damage. 5) congenital anomaly/birth defect and 6) important medical events (IME) that may not 489 490 result in death, be life threatening, or require hospitalization may be considered a serious 491 adverse drug experience when, based upon medical judgment, they may jeopardize the patient 492 or subject and may require medical or surgical intervention to prevent one of the outcomes 493 listed in this definition. Another resource for defining SAE is the Common Terminology Criteria 494 for Adverse Events (CTCAE) - a descriptive terminology for AE reporting (36). CTCAE 495 categorizes AE into Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe or medically 496 significant but not immediately life-threatening), Grade 4 (life-threatening consequences), and 497 Grade 5 (death). Considering both the definition from FDA CFR title 21 and CTCAE, we defined 498 an AE as SAE if it results in hospitalization or death.

- In this study, to identify SAEs for patients treated with Donepezil or FOLFOX4, we first identified the reported SAEs in the Result section of the selected trials from ClinicalTrails.gov. For each SAE, we first collected the ICD-9/10-CM codes to identify corresponding health conditions (Supplementary Table). To further identify SAEs, we mapped these terms to the CTCAE terms and categorized them as SAEs based on the grading scale above (i.e., CTCAE Grade 3/4 and 5).
- **Poisson factor analysis.** By collecting all patient vectors, we can construct a binary data matrix 506 $X \in \{0, 1\}^{V \times N}$, with *V* corresponding to the number of features and *N* being the number of 507 patients. Poisson factor analysis (PFA) (37) assumes *X* following a Poisson likelihood as
- 508

$X \sim Poisson(\Phi \Theta)$

where $\Phi = [\phi_1, \dots, \phi_K] \in \mathcal{R}_+^{V \times K}$ is the topic matrix with each column ϕ_k being the *k*-th clinical topic, and ϕ_k is a distribution over features; $\Theta = [\theta_1, \dots, \theta_N] \in \mathcal{R}_+^{K \times N}$ is the topic weight matrix and each column θ_n represents the topic weights of the *n*-th patient. Based on the expectation rule, we have the equation:

513

$$x_n = \Phi \theta_n = \phi_1 \theta_{n1} + \phi_2 \theta_{n2} + \dots + \phi_K \theta_{nK}.$$

514 Clearly, each patient vector is composed of weighted summation of all topics, where values in 515 θ_n denotes the weights. Therefore, we call θ_n as topic weights, a new representation for x_n , 516 since it exhibits the weight (or proportion after normalization) of each topic in representing the 517 patient x_n . We will perform clustering on the learned new representations.

518

519 Compared with latent Dirichlet allocation (LDA) (38), which models the distribution of topic 520 weights as Dirichlet distribution, PFA models it as Gamma distribution. The advantage of 521 Gamma distribution for topic weight is that it introduces the shrinkage mechanism to prune 522 inactive factors and enhances the model interpretability (39). From Fig. 4b and Fig. 6b we can 523 see that although we set the number of topics as 40 for both cases, after learning, our model 524 automatically truncates it to 35 for AD and 26 for CRC. It is in accordance with the fact that CRC 525 has less samples which thus can be described with less topics. **Clustering with supervised PFA models.** The original PFA is purely unsupervised. In order to incorporate the outcome information (i.e., having SAE or no) into the topic learning process, we extended the original PFA model to a supervised setting which uses the occurrence of SAE as the supervision information to guide the learning process of PFA. Specifically, for the *n*-th patient, if he/she did not encounter any SAE in the follow-up period, we set $y_n = 0$; otherwise, we set $y_n = 1$. Then we adopted the mean-field variational Bayes method (40) to maximize the evidence lower bound (ELBO) of the data likelihood as

533 $ELBO = \sum_{n=1}^{N} \mathbb{E}_{q(\theta_n)} [\log p(x_n | \Phi, \theta_n)] \cdot \sum_{n=1}^{N} \mathbb{E} \left[\frac{q(\theta_n)}{p(\theta_n | r)} \right],$

where $p(x_n | \Phi, \theta_n)$ and $p(\theta_n | \mathbf{r})$ are the Poisson likelihood and Gamma prior as in PFA, $q(\theta_n)$ is the variational posterior to be learned. Currently, we built $q(\theta_n)$ as an encoder network $q_W(\theta_n | x_n)$, where *W* represents learnable parameters of the encoder network, and $q(\cdot)$ is modeled as a Weibull distribution that makes θ_n positive and sparse (41).

- 538 To perform supervised learning, we added a supervised regularizer in the original ELBO 539 objective as
- 540 $L = ELBO + \sum_{n=1}^{N} \log p_{W_c}(y_n | \theta_n),$

541 where the second term can be viewed as the label likelihood implemented by cross entropy loss. 542 The model structure of supervised PFA is shown in Figure 1. As a result, we built a probabilistic 543 auto-encoding supervised topic model, whose parameters were encoder parameters W, 544 decoder parameters Φ (topics), and classifier W_c . We deployed stochastic gradient descent to 545 learn W and W_c , and stochastic gradient based Monte Carlo Markov Chain sampling to infer Φ 546 (41). Our proposed model can be learned in a mini-batch style, which is easily amenable for 547 large-scale data analysis.

548 **Mean topic weight (MTW) and Mann–Whitney U (MWU) test.** In our analysis, we use MTW to 549 select typical topics and plot the topic distributions on each cluster (pie plot in Fig. 3b). 550 According to the data generation process of PFA and equation (1), topic weight of *n*-th patient 551 θ_n represents the weights of all topics in representing one patient. For fair evaluation, we 552 normalize θ_n as $\tilde{\theta}_n = \theta_n / \sum_k \theta_{nk}$ to a Dirichelt distribution (38). As a result, $\tilde{\theta}_n$ can be regarded 553 as topic proportions. Given a group with *N*['] patients, the MTW of *k*-th topic within this group is

554 calculated as $\sum_{n=1}^{N'} \tilde{\theta}_{nk}/N'$. For each topic, after calculation of MTW on SAE subgroup and 555 non-SAE subgroup, we use MWU test (18) to calculate the p-value of each topic for evaluating 556 the significant difference of topic weights on two subgroups.

557 Data availability

558

559 The real data analyzed in this article were provided by OneFlorida Clinical Research 560 Consortium and restrictions apply to the availability of these data. Requests for access to the 561 data should be submitted to and approved by OneFlorida Clinical Research Consortium.

562 Code availability

564 The implementation of the proposed algorithm in python are publicly available from 565 <u>https://github.com/haozhangWCM/Submission-to-NC-SPFA-for-EC</u>.

566 **IRB Information**

567

568 This study has been reviewed by the University of Florida Institute Review Board under 569 protocols IRB202003137 and IRB202000704.

570 **References**

- 571
- Hariton E, Locascio JJ. Randomised controlled trials—the gold standard for effectiveness research. BJOG: an international journal of obstetrics and gynaecology. 2018;125(13):1716.
- Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, et al. Modernizing
 eligibility criteria for molecularly driven trials. Journal of Clinical Oncology. 2015;33(25):2815-20.
- Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly
 patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA
 internal medicine. 2014;174(11):1868-70.
- Banzi R, Camaioni P, Tettamanti M, Lucca U. Older patients are still under-represented in clinical trials of Alzheimer's disease. Alzheimer's research & therapy. 2016;8(1):1-10.
- 581 5. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. Am Fam Physician. 2013;87(5):331-6.
- Smits M, Zegers M, Groenewegen PP, Timmermans DR, Zwaan L, van der Wal G, et al.
 Exploring the causes of adverse events in hospitals and potential prevention strategies. Qual Saf Health Care. 2010;19(5):e5.
- 586
 587
 588
 7. Ory M, Resnick B, Jordan PJ, Coday M, Riebe D, Ewing Garber C, et al. Screening, safety, and adverse events in physical activity interventions: collaborative experiences from the behavior change consortium. Ann Behav Med. 2005;29 Suppl:20-8.
- Li Q, He Z, Guo Y, Zhang H, George TJ, Hogan W, et al. Assessing the Validity of a a priori Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study. AMIA Annu Symp Proc. 2019;2019:1101-10.
- FDA-2019-D-1264. Enhancing the Diversity of Clinical Trial Populations Eligibility Criteria,
 Enrollment Practices, and Trial Designs Guidance for Industry. 2019.
- 595 10. Shenkman E, Hurt M, Hogan W, Carrasquillo O, Smith S, Brickman A, et al. OneFlorida Clinical
 596 Research Consortium: linking a clinical and translational science institute with a community 597 based distributive medical education model. Academic Medicine. 2018;93(3):451.
- 598 11. NCT00478205 Cgl. Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg
 599 Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease:
 600 https://clinicaltrials.gov/ct2/show/NCT00478205; 2007 [
- 12. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) 2020 [Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
- McInnes L, Healy J, Melville J. UMAP: uniform manifold approximation and projection for dimension reduction. arXiv. arXiv preprint arXiv:1802.03426. 2018.
- 605 14. Blei DM. Probabilistic topic models. Communications of the ACM. 2012;55(4):77-84.
- 5. Syed S, Spruit M, editors. Full-text or abstract? examining topic coherence scores using latent
 dirichlet allocation. 2017 IEEE International conference on data science and advanced analytics
 (DSAA); 2017: IEEE.

- 16. Lleti R, Ortiz MC, Sarabia LA, Sánchez MS. Selecting variables for k-means cluster analysis by
 using a genetic algorithm that optimises the silhouettes. Analytica Chimica Acta. 2004;515(1):87100.
- 612 17. Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis.
 613 Journal of computational and applied mathematics. 1987;20:53-65.
- Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger
 than the other. The annals of mathematical statistics. 1947:50-60.
- 616 19. Li Y, Nair P, Lu XH, Wen Z, Wang Y, Dehaghi AAK, et al. Inferring multimodal latent topics from
 617 electronic health records. Nature communications. 2020;11(1):1-17.
- 618 20. Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and 619 safety. Expert opinion on drug safety. 2011;10(5):751-65.
- 21. Long J, Zhang C-J, Zhu N, Du K, Yin Y-F, Tan X, et al. Lipid metabolism and carcinogenesis,
 cancer development. American journal of cancer research. 2018;8(5):778.
- 622 22. Di Stadio A, Ralli M, Roccamatisi D, Scarpa A, Della Volpe A, Cassandro C, et al. Hearing loss
 623 and dementia: radiologic and biomolecular basis of their shared characteristics. A systematic
 624 review. Neurological Sciences. 2021:1-10.
- Wiels W, Baeken C, Engelborghs S. Depressive symptoms in the elderly—An early symptom of
 dementia? A systematic review. Frontiers in pharmacology. 2020;11:34.
- 627 24. Thirunavukkarasu S, Khader SA. Advances in cardiovascular disease lipid research can provide
 628 novel insights into mycobacterial pathogenesis. Frontiers in cellular and infection microbiology.
 629 2019;9:116.
- 630 25. Dhondup T, Qian Q. Acid-base and electrolyte disorders in patients with and without chronic
 631 kidney disease: an update. Kidney Diseases. 2017;3(4):136-48.
- 632 26. Samper-Ternent R, Al Snih S. Obesity in older adults: epidemiology and implications for disability
 633 and disease. Reviews in clinical gerontology. 2012;22(1):10-34.
- 634 27. Chait MM. Gastroesophageal reflux disease: Important considerations for the older patients.
 635 World journal of gastrointestinal endoscopy. 2010;2(12):388.
- 636 28. Baldassarre JS, Kaye D. Special problems of urinary tract infection in the elderly. Medical Clinics
 637 of North America. 1991;75(2):375-90.
- Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Frontiers in immunology. 2012;3:107.
- 640 30. Katz S, Feldstein R. Inflammatory bowel disease of the elderly: a wake-up call. Gastroenterology
 641 & hepatology. 2008;4(5):337.
- Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening Eligibility Criteria to
 Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of
 Cancer Research Joint Research Statement. J Clin Oncol. 2017;35(33):3737-44.
- 32. Liu R, Rizzo S, Whipple S, Pal N, Pineda AL, Lu M, Arnieri B, Lu Y, Capra W, Copping R, Zou J.
 Evaluating eligibility criteria of oncology trials using real-world data and Al. Nature. 2021 Apr 7:15.
- 648 33. Lundberg S, Lee SI. A unified approach to interpreting model predictions. arXiv preprint
 649 arXiv:1705.07874. 2017 May 22.
- 34. Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Mapping ICD-10 and ICD-10-CM
 Codes to Phecodes: Workflow Development and Initial Evaluation. JMIR Med Inform.
 2019;7(4):e14325.
- 35. U.S. Food & Drug Administration (FDA). CFA Code of Federal Regulations: Title 21: Food and drugs [updated Apr 1, 2020]. Available from:
- 655 <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32</u>.

- 36. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) 2020
 [updated Sep 21, 2020]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
- 37. Zhou M, Hannah L, Dunson D, Carin L, editors. Beta-negative binomial process and Poisson
 factor analysis. Artificial Intelligence and Statistics; 2012: PMLR.
- 38. Blei DM, Ng AY, Jordan MI. Latent dirichlet allocation. the Journal of machine Learning research.
 2003;3:993-1022.
- 39. Zhang H, Chen B, Cong Y, Guo D, Liu H, Zhou M. Deep autoencoding topic model with scalable
 hybrid Bayesian inference. IEEE Transactions on Pattern Analysis and Machine Intelligence.
 2020.
- 40. Jordan MI, Ghahramani Z, Jaakkola TS, Saul LK. An introduction to variational methods for
 graphical models. Machine learning. 1999;37(2):183-233.
- 41. Zhang H, Chen B, Guo D, Zhou M. WHAI: Weibull hybrid autoencoding inference for deep topic
 modeling. arXiv preprint arXiv:180301328. 2018.
- 670

671 Acknowledgements

672

The work from JX, HZ and FW was supported by NSF 1750326, ONR N00014-18-1-2585 and NIH RF1AG072449. The work from JB and HZ was supported by NIH R21AG068717 and NIH R21CA253394.

676 Author contributions

677

FW and BJ conceived the study. JX and HZ designed and implemented the algorithm. HZ
analyzed the data. JX and HZ drafted the manuscript. All authors polished and proofread the
manuscript.

681 **Competing interests**

682

683 None declared.

684 685 686

687 688

689

690

691

693 Figure Legends

694

Fig. 1: Model overview. Clinical events including demographics, diagnoses, and medications were extracted from RWD to represent patients. Supervised Poisson factor analysis (PFA) is applied to identify patient subgroups with coherent clinical latent topics and outcomes measured by SAEs. Subgroups with less SAEs can be derived to inform the design of clinical trial eligibility criteria.

700

Fig. 2: The donepezil trial for Alzheimer's disease. a Definition of key dates; b Selection of
 target population; c Traits distribution with UMAP among two patients' groups with or without
 SAE.

Fig. 3: Clustering results of AD target population. a Data visualization with UMAP; **b** Topic distributions of each cluster; **c** Top clinical features from certain disease topics, where the red, blue, and green topics represent the commonly used topics for clusters 4, 5, 6 (most of samples are with SAE>0), clusters 1, 2, 3 (most of samples are with SAE=0), and all clusters, respectively.

709

Fig. 4: Donepezil clinical trial. a Visualization of clustering results; b Mean topic weight (MTW)
of all topics on two groups, where x-axis is the topic index and y-axis is the MTW of each topic
on two subgroups.

713

Fig. 5: The Bevacizumab (Avastin) clinical trial for colon cancer. a Definition of key dates; b
Selection of the target population; c Traits distribution with UMAP among the two patients'
groups with or without SAEs.

Fig. 6: Bevacizumab (Avastin) clinical trial. a Visualization of clustering results; b Mean topic
 weight for 40 topics where x-axis is the topic and y-axis is the proportion of each group in that
 topic.

721

722 Fig. 7: Top clinical features from disease topics in Bevacizumab (Avastin) clinical trial.

- 723
- 724

725 **Table 1**. Demographic characteristics and selected traits of the target population of the 726 donepezil trial for Alzheimer's disease.

Characteristic	Overall (N=4,998)	# SAEs = 0 (N=3,063)	# SAEs > 0 (N=1,935)	χ^2 p-value	Adjust Demo*
Age, Mean (SD), yr	77.53 (9.9)	76.98 (9.8)	78.41 (9.9)		
Sex, No. (%)					
Female	3,123 (62.5)	1,923 (62.8)	1,200 (62.0)		
Race/Ethnicity, No. (%)					
White	3,537 (70.8)	· · ·	,		
Black	965 (19.4)	484 (158)	481 (24.9)		
Asian	34 (0.6)	25 (0.8)	9 (0.5)		
Others & Unknown	462 (9.2)	292 (9.5)	170 (8.8)		
Study traits, No. (%)					
Memantine	1,511 (30.2)	950 (31)	561 (28.9)	0.129	0.14
Psychiatric disorders	1,396 (27.9)	754 (24.6)	642 (33.1)	≤0.001	≤0.00
Cardiovascular (CS*)	1,082 (21.6)	492 (16)	590 (30.4)	≤0.001	≤0.00
Endocrine (CS*)	813 (16.2)	353 (11.5)	460 (23.7)	≤0.001	≤0.00
Cancer	808 (16.1)	468 (15.2)	340 (17.5)	0.032	0.09
Dysphagia	649 (12.9)	302 (9.8)	347 (17.9)	≤0.001	≤0.00
Gastrointestinal (CS*)	631 (12.6)	289 (9.4)	342 (17.6)	≤0.001	≤0.00
Drug or alcohol abuse	. ,	. ,	. ,		
or dependence	627 (12.5)	283 (9.2)	344 (17.7)	≤0.001	≤0.00
Respiratory (CS*)	586 (11.7)	249 (8.1)	337 (17.4)	≤0.001	≤0.00
AD with delirium	389 (7.7)	161 (5.2)	228 (11.7)	≤0.001	≤0.00
Hepatic disease	361 (7.2)	180 (5.8)	181 (9.3)		≤0.00
Renal (CS*)	342 (6.8)	135 (4.4)			≤0.00
Parkinson disease	329 (6.5)	176 (5.7)	153 (7.9)		0.00
Menopausal	230 (4.6)	128 (4.1)	102 (5.2)		0.04
Antidepressant	226 (4.5)	143 (4.6)	83 (4.2)		0.59
Basal/squamous	- (-)	- (-)			
cell carcinoma of the skin	216 (4.3)	128 (4.1)	88 (4.5)	0.532	0.27
Gastric ulcers	163 (3.2)	75 (2.4)	88 (4.5)		≤0.00
Inflammatory bowel disease	154 (3)	82 (2.6)	72 (3.7)	0.038	0.02
Rivastigmine	153 (3)	121 (3.9)	32 (1.6)		≤0.00
Multi-infarct dementia	151 (3)	72 (2.3)	79 (4)		0.00
Acupressure	119 (2.3)	54 (1.7)	65 (3.3)		0.002
Fecal incontinence	107 (2.1)	48 (1.5)	59 (3)		0.00
Galantamine	35 (0.7)	18 (0.5)	17 (0.8)		0.19
Severe lactose intolerance	24 (0.4)	12 (0.3)	12 (0.6)		0.219
Hepatic (CS*)	24 (0.4)	9 (0.2)	11 (0.5)		0.105

727 728 CS*: Clinically significant. If the disease causes hospitalization, we consider it as "clinically significant". Demo*: Demographics (i.e., age, gender and race).

Table 2. Demographic characteristics and selected traits of the target population of thebevacizumab (Avastin) clinical trial for colorectal cancer.

Characteristic	Overall (N=739)	# SAEs = 0 (N=347)	# SAEs > 0 (N=392)	χ^2 p-value	Adjust Demo*
Sex, No. (%)			,		
Female	328 (44.3)	141 (40.6)	187 (47.7)		
Race/Ethnicity, No. (%)					
White	488 (66.0)	237 (68.3)	251 (64)		
Black	172 (23.3)	79 (22.8)	93 (23.7)		
Asian	10 (1.4)	5 (1.4)	5 (1.2)		
Others & Unknown	69 (9.3)	26 (7.5)	43 (10.9)		
traits, No. (%)					
Colon carcinoma	616 (83.3)	296 (85.3)	320 (81.6)	0.182	0.058
Metastatic disease	499 (67.5)	221 (63.6)	278 (70.9)	0.036	0.020
parenteral anticoagulants	240 (32.4)	77 (22.1)	163 (41.5)	≤0.001	≤0.00
immunotherapy	146 (19.7)	75 (21.6)	71 (18.1)	0.233	0.130
anti-angiogenic treatment	137 (18.5)	72 (20.7)	65 (16.5)	0.146	0.08
myocardial infarction	90 (12.1)	25 (7.2)	65 (16.5)	≤0.001	≤0.002
Significant traumatic injury	40 (5.4)	16 (4.6)	24 (6.1)	0.365	0.379
thrombolytic agent	38 (5.1)	9 (2.5)	29 (7.3)	0.003	0.003
central nervous disease	37 (5)	12 (3.4)	25 (6.3)	0.070	0.099
inability to take oral medication	33 (4.4)	10 (2.8)	23 (5.8)	0.050	0.034
Open biopsy	30 (4)	17 (4.8)	13 (3.3)	0.277	0.282
radiotherapy	24 (3.2)	10 (2.8)	14 (3.5)	0.598	0.790
bone fracture	21 (2.8)	8 (2.3)	13 (3.3)	0.410	0.392
coagulopathy	20 (2.7)	8 (2.3)	12 (3)	0.528	0.672
oophorectomy	17 (2.3)	7 (2)	10 (2.5)	0.630	0.956
cerebrovascular accidents	14 (1.8)	5 (1.4)	9 (2.2)	0.396	0.428